About Hanny Al-Samkari, MD

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130

Medical Education

  • MD, Washington University
  • Residency, Hospital of the University of Pennsylvania
  • Fellowship, Dana Farber Cancer Institute
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Hematology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Al-Samkari specializes in conducting research on non-malignant hematologic diseases, with a focus on disorders of hemostasis, thrombosis, and hemolysis. He runs clinical trials of new medications to treat hereditary hemorrhagic telangiectasia (HHT), autoimmune hematologic conditions (such as immune thrombocytopenia, antiphospholipid antibody syndrome and autoimmune hemolytic anemia), hematologic complications of cancer (particularly chemotherapy-induced thrombocytopenia), and hereditary red cell disorders (including pyruvate kinase deficiency and thalassemia). He has has published over 140 peer-reviewed manuscripts and numerous book chapters. His original research has been featured in The New England Journal of Medicine, The Lancet, Annals of Internal Medicine and Blood, among other top peer-reviewed journals in hematology and medicine. Additionally, he is the current Executive Editor of Hematology: The ASH Education Program, an American Society of Hematology peer-reviewed publication.

Publications

  • Selected publications:

    Al-Samkari H, Galact?ros F, Glenth?j A, Rothman JA, Andres O, Grace RF, Morado-Arias M, Layton DM, Onodera K, Verhovsek M, Barcellini W, Chonat S, Judge MP, Zagadailov E, Xu R, Hawkins P, Beynon V, Gheuens S, van Beers EJ; ACTIVATE Investigators. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. New England Journal of Medicine 2022 Apr 14;386(15):1432-1442.

    Al-Samkari H, Kasthuri RS, Parambil JG, Albitar HA, Almodallal YA, V?zquez C, Serra MM, Dupuis-Girod S, Wilsen CB, McWilliams JP, Fountain EH, Gossage JR, Weiss CR, Latif MA, Issachar A, Mei-Zahav M, Meek ME, Conrad M, Rodriguez-Lopez J, Kuter DJ, Iyer VN. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica 2021 Aug 1;106(8):2161-2169.

    Al-Samkari H, Gupta S, Karp Leaf R, Wang W, Rosovsky RP, Brenner SK, Hayek SS, Berlin H, Kapoor R, Shaefi S, Melamed ML, Sutherland A, Radbel J, Green A, Garibaldi BT, Srivastava A, Leonberg-Yoo A, Shehata AM, Flythe JE, Rashidi A, Goyal N, Chan L, Mathews KS, Hedayati SS, Dy R, Toth-Manikowski SM, Zhang J, Mallappallil M, Redfern RE, Bansal AD, Short SA, Vangel MG, Admon AJ, Semler MW, Bauer KA, Hern?n MA, Leaf DE; STOP-COVID Investigators. Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. Annals of Internal Medicine 2021 May;174(5):622-632.

    Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JC, Fogerty AE, Waheed A, Goodarzi K, Bendapudi P, Bornikova L, Gupta S, Leaf D, Kuter DJ, Rosovsky RP. COVID-19 and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection. Blood 2020 Jul 23;136(4):489-500.

    Al-Samkari H. Hereditary Hemorrhagic Telangiectasia: Systemic Therapies, Guidelines, and an Evolving Standard of Care. Blood 2021 Feb 18;137(7):888-895.

    Al-Samkari H, Kolb-Sielecki J, Safina SZ, Xue X, Jamieson BD. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Haematology 2022 Mar;9(3):e179-e189.

    Parambil JG, Gossage JR, McCrae KR, Woodard TD, Menon KVN, Timmerman KL, Pederson DP, Sprecher DL, Al-Samkari H. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. Angiogenesis 2022 Feb;25(1):87-97.

    Ayad N, Grace RF, Kuter DJ, Al-Samkari H. Long-Term Risk of Developing Immune Thrombocytopenia and Hematologic Neoplasia in Adults with Mild Thrombocytopenia. Blood 2022 Dec 29;140(26)2849-2852.

    Complete List of Publications on PubMed: Click Here

Reviews: Comments and Ratings

4.7out of 5(70 Ratings, 27 Comments)

December 2024

Explained things well. Listened carefully.


November 2024

Dr. Al-Samkari is a very busy doctor, yet he has been very generous with his time to assist me when needed. He makes you feel like you are his only patient by the way he listens and compassionately communicates. I have great confidence in Dr. Al-Samkari.


November 2024

Dr Al-Samkari was so nice and patient with me. I was nervous and he was able to explain what could be going on with my blood and set up next steps to continue monitoring my levels. He's a very kind doctor.


October 2024

I just want to say thank you so much and really appreciate Dr. nurse everyone that work in the office provider. They so helpful very nice friendly everything everyone they are amazing nothing else to complain. Everything is great. Perfect I'm so happy with this provider again thank you so much..


October 2024

Dr. Al-Samkari is compassionate, knowledgeable, and extremely thorough.


October 2024

He is the best!


October 2024

Always listens to my thoughts & concerns. I never feel rushed.


September 2024

He's always attentive, knowledgeable and accessible.


September 2024

The whole team is great. I trust them with my care


September 2024

Very caring and thorough, good communicator, knowledgeable, kind.

View More
Ratings and Comments Powered by NRC Health